Presentation is loading. Please wait.

Presentation is loading. Please wait.

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Published byReynard Lane Modified over 6 years ago

Similar presentations

Presentation on theme: "A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,"— Presentation transcript:

1 A randomized multicenter study evaluating Xolair persistence of response after long- term therapy 
Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma, MS, Theodore A. Omachi, MD, MBA, Karin Rosén, MD, Bradley E. Chipps, MD, Allan T. Luskin, MD, Paul G. Solari, MD  Journal of Allergy and Clinical Immunology  Volume 140, Issue 1, Pages e2 (July 2017) DOI: /j.jaci Copyright © 2016 The Authors Terms and Conditions

2 Fig 1 Subject disposition. Physician decision withdrawals took place because of protocol violations (eg, dosing not per US prescribing information and not meeting inclusion/exclusion criteria). Patient decision withdrawals were initiated by the subject for a variety of reasons that were not consistently captured. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

3 Fig 2 Time to first protocol-defined asthma exacerbation.
Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

4 Fig 3 Mean (SD) change in ACT and ACQ scores from baseline to week 52.
Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

5 Fig 4 Eosinophils over time by treatment cohort and exacerbation status. *At baseline, the difference in eosinophil counts was statistically significant for the placebo groups with and without exacerbations (P < .001). Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

6 Fig 5 Feno (in parts per billion) values over time by treatment cohort and exacerbation status. Journal of Allergy and Clinical Immunology  , e2DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

Download ppt "A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,"

Similar presentations

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.
The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma 

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma 
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A
The Editors' Choice Journal of Allergy and Clinical Immunology

The Editors' Choice Journal of Allergy and Clinical Immunology
Dennis K. Ledford, MD, Sally Wenzel, MD 

Dennis K. Ledford, MD, Sally Wenzel, MD 
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy  Allen Kaplan, MD, Dennis Ledford,
Serum periostin is associated with type 2 immunity in severe asthma

Serum periostin is associated with type 2 immunity in severe asthma
NAEPP Expert Panel Report

NAEPP Expert Panel Report
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients  William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients  William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,

Similar presentations

Ads by Google